Eli Lilly and Company has released its fourth-quarter financial results for 2024, showcasing robust revenue growth driven by its blockbuster weight-loss drugs, Mounjaro and Zepbound.
Here are the key highlights from the report:
Revenue Growth
- Revenue Increase: Eli Lilly reported a significant 45% increase in revenue to $13.53 billion compared to Q4 2023, primarily due to a rise in volume sales.
- Volume Drivers: The growth was largely driven by Mounjaro and Zepbound, with sales reaching $3.53 billion and $1.91 billion respectively.
Earnings Performance
- Adjusted EPS Beats Expectations: Despite falling short on some metrics, Eli Lilly’s adjusted earnings per share (EPS) of $5.32 exceeded analyst expectations.
- Reported EPS: The company reported EPS of $4.88 per share on a GAAP basis.
Pipeline Developments
- Zepbound Approval for Sleep Apnea: Notable pipeline progress included the FDA approval of Zepbound for treating moderate-to-severe obstructive sleep apnea in adults with obesity.
- Omvoh Approval for Crohn’s Disease: Additionally, Omvoh received approval for moderately to severely active Crohn’s disease in the U.S..
Guidance for 2025
Eli Lilly provided guidance for fiscal year 2025:
- Revenue Projection: Expected between $58 billion and $61 billion.
- EPS Range: Projected between $22.05 and $23.55 on a GAAP basis.
- Adjusted EPS Range: Anticipated between $22.50 and $24.00 per share.
Stock Response
Following the release of these results, Eli Lilly’s stock experienced mixed reactions due to slightly lower-than-projected revenue figures despite strong earnings performance.
Analysts remain bullish on the stock with most maintaining “buy” ratings over recent months as shares have shown resilience with gains over the past year.
Overall, while some sales figures fell slightly short of expectations due to lower realized prices, Eli Lilly’s strategic investments in new products continue to drive growth momentum into the new year.
Also Read